Esophageal cancer (EC) is a highly fatal malignancy. In the USA, approximately 17,750 people are diagnosed with EC each year, with 16,080 deaths from EC for the same year \[[@ref1]\]. Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) account for more than 95% of EC cases \[[@ref2]\]. Although the incidence of ESCC in the USA has declined, the incidence of EAC has increased dramatically over the last few years. However, ESCC still remains dominant worldwide \[[@ref3], [@ref4]\].

Some risk factors associated with ESCC have been identified in the studies. It is estimated that around 90% of the ESCC cases in the USA are due to smoking, alcohol consumption, and a lower intake of fruits and vegetables. The importance of certain risk factors varies considerably in other parts of the world. In Iran and other Asian countries, the main risk factors for SCC are not well-understood but are thought to be poor nutritional status, low fruit and vegetable intake, and higher temperatures of beverage consumption \[[@ref5]--[@ref8]\].

At the time of diagnosis, 50--80% of the EC patients have locally-advanced or metastatic disease, regardless of histology \[[@ref6]\]. While surgery alone may be curative in early stages of the disease, multimodality treatments, including definitive chemoradiotherapy (CRT) and neoadjuvant chemoradiation (NCRT), followed by surgery is recommended for most locally-advanced EC cases. The 5-year survival rate for locally-advanced cases rarely exceeds 30% \[[@ref9], [@ref10]\].

Previous studies have reported that stage, Glasgow Prognostic Score, neutrophil-to-lymphocyte ratio, serum squamous cell carcinoma antigen and cytokeratin-19 are the important prognostic markers for ESCC \[[@ref11]--[@ref15]\]. This study aims to investigate the factors affecting survival in ESCC patients.

MATERIALS AND METHODS {#sec1-2}
=====================

Patients {#sec2-1}
--------

Medical record of ESCC patients who were followed up and treated at the oncology clinic between 2008 and 2016 were included in this retrospective study. Histological subtypes other than ESCC, patients \<18 years of age, patients with multiple malignancies, patients with missing data were excluded from the analysis. A total of 107 eligible patients were included for the analysis in this study.

Data Collection {#sec2-2}
---------------

The following parameters for each patient were collected from the medical records: age, gender, comorbidities (hypertension, diabetes mellitus, chronic ischemic heart disease, and chronic obstructive pulmonary disease), smoking status, alcohol consumption, initial symptoms, Eastern Cooperative Oncology Group performance status (ECOG-PS), tumor grade, presence of obstruction, treatments \[NACRT, chemotherapy(CT), surgery\], treatment regimens \[carboplatin-paclitaxel (CP) or cisplatin-5- Fluorouracil (CF)\], clinical tumor stage, the site of recurrence or metastasis, and primary tumor localization. The patients were staged according to findings of thoracoabdominal computed tomography and/or PET/CT. NACRT or definitive CRT was given with CF or CP. Radiotherapy was delivered at a total dose of 50.4--66.0 Gy given in 28--35 fractions of 1.8--2.0 Gy per fraction in definitive CRT and total dose of 41.4--50.4 Gy given in 23--28 fractions of 1.8 Gy per fraction in NACRT. Patients were divided into two groups according to ECOG-PS as follows: ECOG-PS 0--2 and ECOG-PS 3--4. Tumor grades were stratified into two groups as follows; grade 1--2 and grade 3. Overall survival (OS) was calculated as the time from the date of diagnosis to the date of death or last follow-up.

Statistical Analysis {#sec2-3}
--------------------

Statistical Package for Social Sciences 22.0 for Windows software (Armonk NY, IBM Corp. 2013) was used for the statistical analysis. Descriptive statistics for categorical variables were given as number and percentage. Descriptive statistics for numerical variables were presented as mean, standard deviation, minimum and maximum. Chi-square analysis was used to compare the ratios in the groups. Monte Carlo simulation was applied when the conditions were not met. The determinant factors were examined by Cox Regression Analysis. The backward stepwise model was used for p\<0.150 values in univariate analysis. Survival analyzes were performed by Kaplan Meier Analysis. The statistical significance level was accepted as p\<0.05.

Ethical Approval {#sec2-4}
----------------

This study was conducted in accordance with the Declaration of Helsinki and reviewed and approved by the Ethics Committee of the Okmeydani Training and Research Hospital, University of Health Sciences, with the decision number 48670771-514.10.

RESULTS {#sec1-3}
=======

Of the 107 patients, 55 (55.1%) were male and 52 (48.6%) were female. The mean age was 60.8±12.8 (range, 27--95) years. Thirty-one (29.0%) patients had hypertension, nine (8.4%) patients had diabetes mellitus, six (5.6%) patients had chronic ischemic heart disease, and four (3.7%) patients had chronic obstructive pulmonary disease. The ECOG PS was 3--4 in seven (6.5%) patients ([Table 1](#T1){ref-type="table"}).

###### 

Patient data

                                               Patients (n=107) %   Stage II-III (n=61) %   Stage IV (n=46) %   p
  -------------------------------------------- -------------------- ----------------------- ------------------- -------------
  Gender                                                                                                        
   Female                                      51.4                 39.3                    67.4                **0.004**
   Male                                        48.6                 60.7                    32.6                
  Age (years) Mean±SD                          60.8±12.8            57.5±12.8               64.5±12.0           **0.008**
  Comorbidity                                                                                                   
   HT                                          29.0                 24.6                    34.8                0.250
   DM                                          8.4                  8.2                     8.7                 0.927
   CIHD                                        5.6                  6.6                     4.3                 0.619
   CPOD                                        3.7                  3.3                     4.3                 0.774
  Smoking                                      50.5                 41.0                    63.0                **0.024**
  Alcohol consumption                          3.7                  0.0                     8.7                 **0.019**
  Symptom                                                                                                       
   Dysphagia                                   89.7                 91.8                    87.0                0.525
   Abdominal pain                              23.4                 23.0                    23.9                0.907
   Weight loss                                 29.0                 23.0                    37.0                0.114
  Presence of obstruction                      49.5                 36.1                    67.4                **0.001**
  ECOG PS                                                                                                       
   0--2                                        93.5                 96.7                    89.1                0.336
   3--4                                        6.5                  3.3                     10.9                
  Grade                                                                                                         
   I-II                                        82.2                 88.5                    73.9                0.051
   III                                         17.8                 11.5                    26.1                
  Clinical-stage                                                                                                
   II                                          26.2                 45.9                                        
   III                                         30.8                 54.1                                        
   IV                                          43.0                                         100.0               
  Primary tumor localization                                                                                    
   Upper 1/3                                   12.1                 9.8                     15.2                0.120
   Middle 1/3                                  57.0                 65.6                    45.7                
   Lower 1/3                                   30.8                 24.6                    39.1                
  Treatments                                                                                                    
   Definitive CRT                                                   27.1                                        
   CRT followed by surgery                                          27.1                                        
   Surgery alone                                                    4.9                                         
  Neoadjuvant CRT regimen                                                                                       
   CP                                          48.3                 48.3                                        
   CF                                          51.7                 51.7                                        
  Definitive CRT regimen                                                                                        
   CP                                          44.8                 44.8                                        
   CF                                          55.2                 55.2                                        
  Surgery                                      35.5                 52.5                    13.0                **\<0.001**
  Recurrence                                                                                                    
   No                                                               55.7                                        
   Local                                                            8.2                                         
   Systemic                                                         36.1                                        
  The site of metastasis at diagnosis                                                                           
   Distant LN                                  41.3                                         41.3                
   Liver                                       26.1                                         26.1                
   Lung                                        30.4                                         30.4                
   Bone                                        10.9                                         10.9                
   Peritoneum                                  6.5                                          6.5                 
  First-line treatment in metastatic setting                                                                    
   CT                                          53.4                 48.1                    56.5                0.489
   BSC                                         46.6                 51.9                    43.5                
  First-line CT regimen                                                                                         
   CF                                          66.7                 46.2                    76.9                0.077
   CP                                          33.3                 53.8                    23.1                
  Final status                                                                                                  
   Dead                                        60.7                 41.0                    87.0                **\<0.001**
   Alive                                       39.3                 59.0                    13.0                

BSC: Best supportive care; CF: Cisplatin-5-florourasil; CIHD: Chronic ischemic heart disease; COPD: Chronic obstructive lung disease; CP: Carboplatin-paclitaxel; CRT: Chemoradiation; CT: Chemotherapy; ECOG PS: Eastern Cooperative Oncology Group Performance Status; DM: Diabetes mellitus; HT: Hypertension; Max.: Maximum; Min.: Minimum; LN: Lymph node; SD: Standard deviation.

Twenty-eight (26.2%) patients had clinical-stage II disease, 33 (30.8%) patients had stage III disease, and 46 (43.0%) patients had stage IV disease. Primary tumor was localized in upper 1/3 esophagus in 13 (12.1%) patients, middle 1/3 esophagus in 61 (57.0%) patients, and lower 1/3 esophagus in 33 (30.8%) patients. Recurrence developed in 27 (44.3%) patients with clinical-stage II to III disease during the follow-up, with five (8.2%) patients and 22 (36.1%) of them being local recurrence and systemic metastasis, respectively. At the time of diagnosis, the site of metastasis was distant lymph nodes (LN) in 19 (41.3%) patients, liver in 12 (26%) patients, lung in 14 (30.4%) patients, bone in five (10.6%) patients, and peritoneum in three (6.5%) patients ([Table 1](#T1){ref-type="table"}).

Of the 38 (35.5%) patients who underwent surgery, 32 (78.9%) had curative surgery. NACRT was given to 29 (27.1%) patients, 14 (48.3%) of whom received concurrent carboplatin (AUC2, iv. on day 1) and paclitaxel (50 mg/m^2^, iv. on day 1) (CP) weekly for five weeks and 15 (51.7%) received concurrent cisplatin (75 mg/m^2^, on days 1 and 29) and 5-Fluorouracil (iv continuous infusion over 24 hours daily on days 1--4 and 29--33) (CF) 35-day cycle. Definitive CRT was given to 29 (27.1%) patients, 13 (44.8%) of whom received carboplatin (AUC2, iv. on day 1) and paclitaxel (50 mg/m^2^ iv on day 1) weekly for five weeks and 16 (55.2%) received cisplatin (75 mg/m^2^ iv on days 1 and 29) and 5-Fluorouracil (1000 mg/m^2^, iv continuous infusion over 24 hours daily on days 1--4 and 29--33) 35-day cycle. Of the 27 patients with the non-metastatic disease at diagnosis who developed recurrence during follow-up, 13 (48.1) received a first-line CT. Among 46 patients with metastatic disease at diagnosis, 26 (56.5%) received CT. During the median follow up time of 24 months, 65 (60.7%) patients died ([Table 1](#T1){ref-type="table"}).

Median overall survival (mOS) was not achieved in clinical-stage II patients, 22.0 (15.8--28.1) months in stage III patients, and 6.0 (4.1--7.8) months in stage IV patients (log rank p\<0.001) ([Fig. 1](#F1){ref-type="fig"}). In clinical-stage II-III patients, mOS could not be reached in patients who underwent surgery following neoadjuvant CRT, whereas mOS was only 22.0 months in patients receiving definitive CRT and 24.0 months in those treated with surgery alone (log rank p=0.008) ([Fig. 2](#F2){ref-type="fig"}). In metastatic stage, mOS was 8.0 months for those treated with first-line CT and 3.0 months for patients receiving best supportive care (log rank p\<0.001) ([Fig. 3](#F3){ref-type="fig"}).

![Overall survival according to the stage at diagnosis.\
mOS: Median overall survival; NR: Not reached; OS: Overall survival.](NCI-7-267-g001){#F1}

![Overall survivals according to the treatment modalities in non-metastatic patients.\
mOS: Median overall survival; OS: Overall survival; CRT: Chemoradiation.](NCI-7-267-g002){#F2}

![Overall survivals according to the treatment modalities in metastatic patients.\
mOS: Median overall survival; OS: Overall survival.](NCI-7-267-g003){#F3}

In the univariate analysis; presenting with dysphagia (Hazard ratio \[HR\], 0.26), ECOG PS (HR, 4.50) undergoing surgery (HR, 0.31), presence of obstruction (HR, 3.62), receiving NACRT (HR, 0.28), stage (HR, 4.09), and experiencing recurrence (HR, 7.30) were the factors affecting survival in patients with stage II-III disease (p=0.016, p=0.049, p=0.006, p=0.003, p=0.003, p=0.004, p=0.003, p=0.001, respectively), while gender (HR, 0.43), smoking (HR, 2.50),--ECOG PS (HR, 3.60), liver metastasis (HR, 3.11), lung metastasis (HR, 0.36), and CT (HR, 0.36) were found to be the factors related to survival in patients with stage IV disease (p=0.025, p=0.018, p=0.014, p=0.001, p=0.001, p\<0.001, respectively) ([Table 2](#T2){ref-type="table"}).

###### 

Univariate analysis for survival according to the stages

                          Stage II-III      Stage IV                                                         
  ----------------------- ----------------- ---------- ------- -------- ----------- ------- ------- -------- -------------
  Gender                  Female vs. male   0.584      0.264   1.290    0.184       0.430   0.206   0.898    **0.025**
  Age                     (year)            1.027      0.993   1.062    0.117       1.000   0.974   1.026    0.986
  HT                      Yes vs. no        1.533      0.658   3.572    0.322       1.205   0.627   2.318    0.575
  DM                      Yes vs. no        1.891      0.555   6.438    0.308       1.314   0.463   3.725    0.608
  CIHD                    Yes vs. no        2.089      0.622   7.014    0.233       1.056   0.253   4.412    0.940
  COPD                    Yes vs. no        1.333      0.179   9.921    0.779       1.246   0.297   5.235    0.764
  Smoking                 Yes vs. no        0.551      0.237   1.280    0.166       2.501   1.174   5.326    **0.018**
  Alcohol consumption     Yes vs. no                                                0.535   0.278   1.706    0.510
  Dysphagia               Yes vs. no        0.260      0.086   0.782    **0.016**   0.459   0.186   1.133    0.091
  Abdominal pain          Yes vs. no        0.731      0.274   1.950    0.531       0.791   0.376   1.664    0.536
  Weight loss             Yes vs. no        0.774      0.290   2.065    0.609       0.716   0.372   1.379    0.318
  ECOG PS                 3--4 vs. 0--2     4.505      1.007   20.164   **0.049**   3.603   1.297   10.009   **0.014**
  Grade                   III vs. I-II      0.216      0.029   1.620    0.136       1.918   0.949   3.879    0.070
  Surgery                 Yes vs. no        0.317      0.139   0.724    **0.006**   1.457   0.606   3.501    0.400
  Obstruction             Yes vs. no        3.627      1.543   8.525    **0.003**   1.294   0.666   2.511    0.447
  Neoadjuvant CRT         Yes vs. no        0.281      0.118   0.668    **0.004**                            
  Stage                   III vs. II        4.096      1.615   10.387   **0.003**                            
  Recurrence              Yes vs. no        7.301      3.027   17.609   **0.001**                            
  Distant LN metastasis   Yes vs. no                                                1.704   1.006   2.885    0.047
  Liver metastasis        Yes vs. no                                                3.117   1.585   6.131    **0.001**
  Lung metastasis         Yes vs. no                                                0.365   0.202   0.658    **0.001**
  Bone metastasis         Yes vs. no                                                0.802   0.251   2.559    0.709
  Peritoneum metastasis   Yes vs. no                                                1.181   0.288   4.833    0.817
  CT vs. BSC                                                                        0.327   0.172   0.620    **\<0.001**

CI: Confidence interval; HR: Hazard ratio; BSC: Best supportive care; CIHD: Chronic ischemic heart disease; COPD: Chronic obstructive lung disease; CRT: Chemoradiation; CT: Chemotherapy; ECOG PS: Eastern Cooperative Oncology Group Performance Status; DM: Diabetes mellitus; HT: Hypertension; LN: Lymph node.

In multivariate analysis, ECOG PS (HR, 6.13), undergoing surgery (HR, 0.22), stage (HR, 3.19), and experiencing recurrence (HR, 24.12) were the factors associated with survival in patients with stage II-III disease (p=0.028, p=0.002, p=0.031, and p\<0.001, respectively), while ECOG PS (HR, 3.31), tumor grade (HR, 3.39), liver metastasis (HR, 2.53), and receiving CT (HR,0.15) were the independent predictors of survival in stage IV patients (p=0.004, p=0.002, p=0.023, and p\<0.001, respectively) ([Table 3](#T3){ref-type="table"}).

###### 

Multivariate analysis for survival according to stages

  Stage II-III   Stage IV                                                                                                         
  -------------- --------------- -------- --------------- ------------- ------------------ --------------- ------- -------------- -------------
  ECOG PS        3--4 vs. 0--2   6.138    1.212--31.075   **0.028**     ECOG PS            3--4 vs. 0--2   3.313   1.141--9.693   **0.004**
  Surgery        Yes vs. no      0.229    0.092--0.570    **0.002**     Grade              III vs. I-II    3.397   1.551--7.439   **0.002**
  Stage          III vs. II      3.195    1.111--9.183    **0.031**     Liver metastasis   Yes vs. no      2.537   1.134--5.672   **0.023**
  Recurrence     Yes vs. no      24.128   6.455--90.180   **\<0.001**   CT vs. BSC                         0.156   0.069--0.348   **\<0.001**

CI: Confidence interval; CT: Chemotherapy; BSC: Best supportive care; ECOG PS: Eastern Cooperative Oncology Group Performance Status; HR: Hazard ratio.

DISCUSSION {#sec1-4}
==========

In this study, we investigated the factors affecting survival in ESCC patients. In non-metastatic disease, undergoing surgery and early stage of the disease increased survival, whereas experiencing recurrence adversely affected survival. In patients with metastatic disease, the presence of ECOG PS 3--4, grade-III histology, and liver metastasis adversely affected survival, whereas CT administration significantly improved survival.

Although the main risk factors for ESCC are not well--understood, it is supposed that malnutrition, low fruit and vegetable consumption, and higher temperatures of food and beverage consumption are the possible risk factors \[[@ref5]\]. In areas where ESCC is endemic, disease has no gender specificity. However, ESCC is more common in men in low incidence areas \[[@ref16]\]. In our study, more than half of the patients were active smokers; however, smoking status in metastatic stage did not affect survival in multivariate analysis although it was associated with survival in univariate analysis. In our study, only 3.7% patients had a history of alcohol consumption. Interestingly, most of the patients with early stage were male, while the majority of the patients in the metastatic stage were female. The reason for the higher number of female patients with metastatic disease may be due to the delay in diagnosis because of late applications to health institutions.

In ESCC, tumoral obstruction of the esophagus causes progressive dysphagia, often accompanied by weight loss. Dysphagia usually occurs when the esophageal lumen diameter is less than 13 mm and this finding indicates advanced disease \[[@ref17]\]. Half of the patients included in the study had obstruction at the time of diagnosis, approximately 90% of the patients had dysphagia, and 29% of the patients had weight loss. The rate of presenting with obstruction at metastatic stage was significantly higher. Three-fourths of patients in the study had locally-advanced or metastatic disease.

RTOG 85--01 study by Al Sarraf et al. \[[@ref18]\] included 123 patients with ESCC or EAC and compared RT to definitive CRT in locally-advanced stage. Sixty-two patients received RT alone and 61 patients received definitive CRT with CF. The mOS in the definitive CRT arm was 14.1 months compared to 9.3 months in the RT alone arm. Later, 69 patients were treated with combined modality approach and the results were reported to be similar to the previous findings, with mOS being 17.2 months. In a study by Stahl et al. \[[@ref19]\], 172 patients with locally-advanced EC were randomized to three cycles of induction CT followed by NACRT and surgery arm or definitive CRT arm. There was no significant difference in mOS between the two groups after a 6-year of follow-up time. The 2-year locoregional control rate was better in patients undergoing surgery. In the metaanalyzes evaluating NACRT studies in EC, NACRT has been shown to provide better results compared to surgery alone \[[@ref20]--[@ref22]\]. In a meta-analysis by Jin et al. \[[@ref20]\], which evaluated 14 randomized trials comparing NACRT to surgery alone, local control rates and survival rates were reported to be better with NACRT than surgery alone. Similarly, in meta-analysis conducted by Urschel et al. \[[@ref21]\], which included nine randomized trials comparing NACRT to surgery alone, both 3-year survival and local control rate were found to be better in the NACRT arm.

In our study, 29 patients were treated with definitive CRT and had mOS of 22 months. In our study, there were no patients who received RT alone, whereas 29 patients underwent surgery following NACRT and mOS could not be reached. Only three patients were treated with surgery alone and had mOS of 24 months. In our study, no adjuvant treatment was administered. In multivariate analysis, undergoing surgery significantly improved survival. Of 29 patients treated with definitive CRT, 14 (49.3%) had recurrence, with 3 (10.3) of them experiencing local recurrence. Of 29 patients who underwent surgery following NACRT, 10 (34.5%) had recurrence, with only one (3.4%) of them experiencing local recurrence. All patients (n=3) who treated with surgery alone developed recurrence, with one (33.3%) of them having local recurrence.

Javle et al. \[[@ref23]\] included 172 EC patients in their analysis, 74 of whom were ESCC. In the study, stage and surgery were found to be independent factors affecting survival. Similarly, Kumagai et al. \[[@ref24]\] found that stage was the independent factor associated with survival in ESCC patients treated with surgery. In our study, clinical-stage and ECOG PS in non-metastatic stage were the factors related to survival. In addition, experiencing recurrence increased the mortality by 24-fold. In non-metastatic disease, undergoing surgery following NACRT decreased mortality by 80%.

It has been shown CT administration in metastatic EC patients prolongs survival and reduces symptoms \[[@ref25], [@ref26]\]. Likewise, it was shown in our study that receiving CT significantly prolonged survival in patients with metastatic disease. In addition, grade 3 histology, liver metastasis, and ECOG PS adversely affected survival in metastatic stage.

The strengths of our study were that this study included only ESCC patients and analyzed metastatic and non-metastatic patients separately. Moreover, median follow-up time was relatively longer. However, its retrospective nature, single-center design, and small sample size were the limitations of the present study.

In conclusion, undergoing surgery, ECOG-PS, stage, and experiencing recurrence were the significant factors associated with survival in patients with the non-metastatic disease, while grade, ECOG PS, liver metastasis, and receiving CT were the independent predictors of survival in patients with metastatic disease.
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